Substance Abuse Associated with Aggressive/Violent Behaviors in Psychiatric Outpatients and Related Psychotropic Prescription

Massimo Carlo Mauri1 · Giovanna Cirnigliaro2 · Eleonora Piccoli2 · Matteo Vismara2 · Vera De Carlo2 · Nicolaja Girone2 · Bernardo Dell’Osso2,3,4,5

Accepted: 9 May 2022 / Published online: 23 May 2022 © The Author(s) 2022

Abstract
Psychiatric disorders with substance abuse are considered the leading causes of most violent and aggressive behaviors in the general population. This study was aimed to assess the impact of substance abuse and the therapeutic approaches adopted by psychiatrists in aggressive vs non-aggressive outpatients (n = 400) attending community-based psychiatric services and recruited over a 3-year period. Clinical and therapeutic variables were collected from medical records and the Modified Overt Aggression Scale (MOAS) was used to assess any aggressive/violent behavior. Violent behaviors were significantly higher in alcohol and substance abusers compared to non-abusers (p < 0.01), except for heroin abusers. Mean weighted MOAS score was significantly higher in patients taking antipsychotics (p < 0.005). The administration of Haloperidol, Zuclopenthixol, and Clozapine was more frequent in aggressive than in non-aggressive patients. The most frequently administered drug in these patients was Haloperidol (23.91%), with a higher mean daily dosage in violent vs non-violent patients. Our results confirm the well-established relationship between substance abuse and violent behaviors in psychiatric inpatients also within outpatient community services. Observed rates of most frequently prescribed antipsychotics to aggressive patients did not show any preference for newer generation compounds, with clinicians operating in the community setting likely being in need for further evidence and specific training to support their treatment choice.

Keywords Aggressive behavior · Violence · Substance abuse · Pharmacological treatment · Antipsychotics · Outpatients

The impact of worldwide violence, included in the top twenty causes of loss of disability-adjusted living years (DALYs) (Wolf et al., 2014), is projected to increase by 2030 (Mathers et al., 2008). Indeed, psychiatric disorders are considered among the leading causes of violent acts in current literature (Arseneault et al., 2000; Brennan et al., 2000; Elbogen & Johnson, 2009; Li et al., 2020). Different studies indicate that the more severe
the disorder, the more prone to commit violent acts patients seem to be (Fazel et al., 2009a, b; Swanson et al., 2002; Witt et al., 2013). The associated use of alcohol and/or other substances of abuse is a frequent complicating factor in psychiatric patients, resulting in an increased risk of aggressive and violent behaviors, especially in the acute phase of the disorder (Fazel et al., 2009a, b, 2010; Ferns & Cork, 2008; McNaughton Reyes et al., 2014; Reyes et al., 2015).

In Italy, as in many other countries, the public mental health system is largely based on a widespread network of community mental health centers (CMHCs): as a result, the majority of people with mental disorders live in the community and can have access to illicit drugs with relative ease. In spite of the territorial dimension of the Italian mental health services, a very limited number of studies investigated the relationship between outpatients’ clinic-therapeutic variables and the occurrence of aggressive/violent behaviors (Pinna et al., 2016). Therefore, to the best of our knowledge, the present study was specifically aimed to investigate the association between aggressive/violent behavior and substance abuse in a sample of psychiatric outpatients attending a community mental health center in Northern Italy.

Clinicians often evaluate aggressive and violent behaviors among psychiatric patients through the Modified Overt Aggression Scale (MOAS) (Foley et al., 2005; He et al., 2017; Yudofsky et al., 1986), which is able to primarily assess aggressive and violent behaviors through four subscales (verbal aggression, aggression against objects, self-aggression, and aggression against others).

As far as the acute management of aggression is concerned, recent guidelines emphasize the importance of specific de-escalation techniques, followed by physical restraint and pharmacotherapy exclusively in the more severe cases. First-line treatments in these situations are antipsychotics and benzodiazepines (Brown et al., 2017; Gillings et al., 2016).

As for the chronic management of persistent aggressive and violent behaviors, no medication has been approved by the American Food and Drug Administration (FDA) or the European Medicines Agency so far. In these contexts, currently used pharmacological interventions often consist of drug combinations on a trial-and-error basis that can elicit side effects that further complicate the overall clinical management of aggressive patients. However, neurobiological considerations combined with real-world data can provide a comprehensive framework for systematic medication trials to manage persistently aggressive patients (Meyer et al., 2016). Ultimately, the primary disorder they have been suffering from is an important variable to consider in the treatment choice.

In the case of psychotic patients, ineffective treatment of psychosis often manifests as violent and aggressive behaviors that warrant treatment strategies that are not evidence-based. These include both antipsychotic polypharmacotherapy and high-dose antipsychotic monotherapy (Morrisette & Stahl, 2013). For instance, Haloperidol is frequently used as monotherapy to handle situations of aggression or agitation for psychotic patients. Apart from being widely accessible, in its intramuscular formulation, it may be the only antipsychotic medication available in limited-resource areas (Ostinelli et al., 2017). Where additional drugs with a better tolerability profile are available, the sole use of Haloperidol may be considered controversial, as it might aggravate violent behavior in a subgroup of patients, probably as a consequence of dysphoria associated with neuroleptic treatment (Mizrahi et al., 2007). These problems can be minimized by using the new-generation antipsychotics (Kirsch et al., 2007; van Schalkwyk et al., 2018). Indeed, in a previous review, Paliperidone-extended release appeared to be the agent with the strongest evidence of efficacy for the management of hostility among inpatients with schizophrenia spectrum
disorders (Victoroff et al., 2014). Anti-aggressive effects have been reported with Risperidone as well (Buckley et al., 1997; Ostinelli et al., 2018a).

According to a more recent review, Clozapine might be more effective than other drugs in reducing aggressive behaviors (Patchan et al., 2018), and its anti-aggressive effect seems to be distinct from its antipsychotic and sedative action (Buckley et al., 1995; Krakowski et al., 2006).

Consensus on the efficacy of other second-generation antipsychotics (SGAs) in treating patients’ aggressiveness is still lacking (Penzner et al., 2009), although studies reported that Olanzapine, Quetiapine, and Aripiprazole showed some effectiveness (Arango & Bernardo, 2005; Lindenmayer & Kanellopoulou, 2009) with no significant difference among them (Mauri et al., 2011). Interestingly, a recent meta-analysis found that antipsychotics were broadly effective for the treatment of aggression, but with effect sizes similar to those of non-pharmacologic interventions. Furthermore, no differences were found in relation to the type of pharmacological agent or the underlying diagnosis, while a small but significant dose effect was identified (van Schalkwyk et al., 2018).

The lack of consensus on the long-term management of aggressiveness in psychiatric patients arouses the need to further investigate the use of specific pharmacological treatments in these individuals, particularly in the outpatient setting, where most individuals are taken care overtime. In a previous report of our group on this specific topic, we observed that diagnosis of personality disorders and specific sociodemographic factors, including employment status, represented major determinants of aggressive and violent behaviors among psychiatric outpatients (Mauri et al., 2019).

In continuity with the abovementioned report (Mauri et al., 2019), the present study focused on the prevalence of substance abuse in violent/aggressive psychiatric patients with different diagnoses attending a territorial service in Milan, Italy. In addition, we analyzed types and dosages of antipsychotic drugs prescribed in the real world to aggressive versus non-aggressive patients, and compared the use of these specific psychotropics.

**Methods**

Patients attending the territorial psychiatric service of zone 1—“Centro Psicosociale” (CPS)—Department of Psychiatry, Ospedale Maggiore Policlinico of Milan, Italy, were assessed over a 3-year period. The service is a public CMHC that provides assistance to post-acute psychiatric outpatients in need of pharmacological, psychological, and social support.

For the purpose of the present study, all psychiatric patients attending the facility were assessed. Inclusion criteria consisted of the occurrence of at least one psychiatric visit for each patient. There was no exclusion in relation to psychiatric diagnosis, psychiatric nor medical comorbidity.

Clinical, socio-demographic, and therapeutic data were collected from patients’ medical records. Diagnoses were formulated by two expert psychiatrists on the basis of the International Classification of Disease, 10th Edition (ICD-10) (World Health Organization, 1993) criteria. We considered as alcohol and substance abuse all those conditions that, according to the ICD-10, are included in “Mental and behavioural disorders due to psychoactive substance use”: acute intoxication, harmful use, dependence syndrome, and withdrawal state.

The Modified Overt Aggression Scale (MOAS) (Foley et al., 2005; He et al., 2017; Yudofsky et al., 1986) was administered to each patient during the follow-up visit at the
CPS. Any aggressive or violent behavior occurring in the week before the contact with the members of the CPS team was retrospectively recorded through the MOAS. A member of the medical staff, who was blind in relation to the clinical diagnosis, quantified the MOAS scores, on the basis of his/her direct observation or the information given by relatives or caregivers that were aware of any clinically relevant information regarding patient’s behavior.

MOAS is a semi-structured interview that evaluates 4 clusters of aggressive behavior: verbal aggression, aggression against objects, self-aggression, and aggression against others. Each subscale score ranges from 0 (no aggression) to 4 (maximum score). The subscales were weighted, as previously reported (Kay et al., 1988). The total MOAS score is the sum of the weighted scores. The prevalence of violent behaviors was calculated considering the presence of a score > 0 in one MOAS subscale other than verbal aggression (e.g., aggression against objects, self-aggression, aggression against others), as done in previous investigation (Foley et al., 2005). In this study, we used the Italian version of MOAS that has been validated in terms of inter-rater reliability and internal consistency by Margari and colleagues (Margari et al., 2005). Additional details on the CPS1 structure and the MOAS have been provided elsewhere (Mauri et al., 2019).

Information regarding psychopharmacological treatments, taken during the period when the visit and the MOAS administration occurred, was collected from medical records and subdivided into the following classes: antipsychotics (oral and long-acting), antidepressants, mood stabilizers, benzodiazepines, and psychotherapy or group therapy.

The protocol was approved by the local Ethics Committee and a written informed consent was obtained from patients or their relatives after receiving a full study description.

Statistical analyses were conducted by means of descriptive methods, analysis of variance (ANOVA), chi-squared test, multifactor analysis of variance (Tukey’s test), and regression analysis (simple regression), using the Statgraphic Centurion version 2018 (2018 Statpoint, Inc. USA, http://www.statgraphics.com).

Results

The study included 400 patients whose mean clinical variables are shown in Table 1.

Violent behaviors were significantly higher in patients with alcohol abuse (p < 0.01), cocaine abuse (p < 0.001), and cannabis abuse (p < 0.001), compared with non-abusers (Fig. 1). No significant difference in subjects with heroine abuse compared with non-abusers emerged in terms of violent behaviors.

The most relevant therapeutic variables, including psychotherapy and group therapy, of the total sample are summarized in Table 2. Mean weighted MOAS scores (MWMOASs) were significantly higher in patients taking antipsychotic drugs (p < 0.005), while they were significantly lower in those taking antidepressants (p < 0.001). No significant correlation with regard to long-acting therapy, mood stabilizers, or anxiolytics was observed (Table 2). No statistically significant difference in MWMOASs was found among patients taking different antipsychotics compared to those taking monotherapies.

MWMOASs were significantly higher in patients who were not currently receiving psychotherapy (2.63 ± 5.52) than in patients who were receiving it (1.26 ± 3.48) (p < 0.05) (Table 2). No significant correlation in regard to group therapy was observed.

Figure 2 shows the different types of antipsychotics utilized in the CPS and how often they were administered in non-aggressive and aggressive patients. The frequency
of Haloperidol, Zuclopenthixol, Clozapine, and Paliperidone administration was higher in aggressive vs non-aggressive patients. In the aggressive population, the most frequently administered drugs were Haloperidol (23.91%), Olanzapine (17.39%), Quetiapine (13.04%), and Zuclopenthixol (10.87%). As shown in Table 2, the mean dosages of

Table 1 Clinical variables of the total sample

| Clinical variables                          | Values                        |
|--------------------------------------------|-------------------------------|
| Age                                        | (49.7 ± 14.72)               |
| **Gender:**                                |                               |
| Male                                       | 52.75%                        |
| Female                                     | 47.25%                        |
| **Diagnosis:**                             |                               |
| Schizophrenia (SCH)                       | 23.31%                        |
| Personality disorder (PD)                  | 13.53%                        |
| Bipolar disorder (BD)                      | 17.04%                        |
| Anxiety disorder (AD)                      | 20.3%                         |
| Major depression (MD)                      | 8.77%                         |
| Mental retardation (MR)                    | 3.76%                         |
| Substance-induced psychosis (SIP)          | 4.51%                         |
| Obsessive–compulsive disorder (OCD)        | 1.75%                         |
| Eating disorder (ED)                       | 0.75%                         |
| Senile dementia (DEM)                      | 2.01%                         |
| Delusional disorder (DD)                   | 4.26%                         |
| **Substance abuse:**                       |                               |
| Cannabis                                   | 15.75%                        |
| Cocaine                                    | 8.75%                         |
| Heroine                                    | 3.75%                         |
| Alcohol                                    | 15.75%                        |
| Age at onset                               | (33.74 ± 15.2)               |
| Duration of illness                        | (15.93 ± 12.25)              |
| **Number of hospitalizations:**            |                               |
| 0                                          | 40%                           |
| 1–5                                        | 40.5%                         |
| 6–9                                        | 6%                            |
| ≥ 10                                       | 13.75%                        |
| **Number of compulsory admissions:**       |                               |
| 0                                          | 83%                           |
| > 0                                        | 17%                           |
| **Number of attempted suicide:**           |                               |
| 0                                          | 82.25%                        |
| 1–3                                        | 16.75%                        |
| 4–6                                        | 1%                            |
| MWMOASs<sup>a</sup>                        | 2.19 ± 5                      |
| MOAS score > 0                             | 21.50%                        |

<sup>a</sup>MWMOASs (mean weighted MOAS score); values for categorical and continuous variables are expressed as percentage (%) and mean ± SD, respectively.
Haloperidol and Zuclopenthixol prescribed in violent patients were higher than those prescribed in non-violent patients.

**Discussion**

Several studies investigated the presence of aggressive and violent behaviors among inpatients of psychiatric wards (Amore et al., 2008; Ballerini et al., 2007; Biancosino et al., 2009; Colasanti et al., 2008; Cornaggia et al., 2011; Dack et al., 2013; Szabo et al., 2015), while studies with outpatients are limited (Amore et al., 2013; Choe et al., 2008; Folgo & Iennaco, 2020; Pinna et al., 2016).

Our study evaluated aggressive and violent behaviors in psychiatric outpatients attending an Italian CMHC of the central area of Milan, focusing on substance abuse and therapeutic variables.

An important variable in aggressive behaviors is, in fact, substance abuse (Fazel et al., 2009a, b, 2010), particularly alcohol (Renwick et al., 2016). In this perspective, a significant relationship between substance and alcohol abuse and violent behavior was observed. In particular, we found a statistically significant correlation for alcohol abuse, cannabinoid and cocaine abuse, and violence, likely related to the activating effects of these substances, as reported in literature (Boles & Miotto, 2003; Fazel et al., 2014; Phillips, 2000). Conversely, heroin abuse did not correlate with violent behaviors. Most data on heroin abusers, in fact, show that violent acts typically occur during abstinence and not during active use (Gerra et al., 2004). When occurring in heroin-addicted patients, moreover, aggressive
Table 2  Therapeutic variables in relation to the mean weighted MOAS score in the total sample (top part); different mean dosage of the most used oral antipsychotics in violent and non-violent patients (bottom part)

| Therapeutic variables | Prevalence % | MWMOASs^a ± SD | p value |
|-----------------------|--------------|----------------|---------|
| N = 400               |              |                |         |
| Pharmacotherapy       |              |                |         |
| Antipsychotics (oral) | 48%          | 52%            | 1.46 ± 4.2 | 2.86 ± 5.59 | 0.005 |
| Antipsychotics (long-acting) | 91%          | 9%             | 2.15 ± 5.1 | 2.54 ± 4.2 | 0.001 |
| Antidepressants       | 70%          | 30%            | 2.71 ± 5.5 | 0.99 ± 3.2 |         |
| Anticonvulsants       | 72%          | 28%            | 1.91 ± 4.6 | 2.90 ± 5.8 |         |
| Anxiolytics           | 53%          | 47%            | 2.45 ± 5.3 | 1.93 ± 4.7 |         |
| Psychotherapy, current | 31.75%       | 68.25%         | 2.63 ± 5.5 | 1.25 ± 3.4 | 0.05   |
| Group therapy, current | 18.50%       | 81.50%         | 1.98 ± 4.8 | 3.12 ± 5.8 |         |
| Non-violent patients  |              |                |         |
| Violent patients      |              |                |         |

| Antipsychotics (oral) | Mean dosage (mg/day) ± SD | Mean dosage (mg/day) ± SD |
|-----------------------|----------------------------|----------------------------|
| Haloperidol           | 6.68 ± 12                  | 8.91 ± 14                  |
| Zuclopentixol         | 22.5 ± 13                  | 59 ± 80                    |

^aMWMOASs (mean weighted MOAS score)
behaviors seem to be mostly correlated with comorbid psychiatric diagnoses (Maremmani et al., 2014). Nevertheless, it needs to be noted that most addicted patients had been taken over by CPS because of their psychiatric comorbidity. Therefore, the potential role played by the psychopathological component or by drug addiction per se on aggression and violence is difficult to understand. Moreover, it is not clear whether these patients had been successfully treated by specific services dedicated to substance addicts (named “Servizi per le dipendenze” [SERD]) and whether patients followed by such services, in comparison to those who were not, had an improvement in relation to aggressive behaviors.

From a pharmacological point of view, in patients with aggressive/violent behaviors, the evidence from RCTs (randomized controlled trials) for the use of benzodiazepines as monotherapy is not solid, while their use in augmentation does not seem to confer a clear advantage and can bring potential adverse effects (Zaman et al., 2017). On the other hand, the efficacy of antiepileptic drugs in reducing aggression and associated impulsivity is very limited (Huband et al., 2014). For these reasons, we focused our analysis to the prescription of antipsychotics rather than benzodiazepines and/or anticonvulsants.

Data on the antipsychotics efficacy in aggressive patients are mixed. Evidence for use of second-generation antipsychotics (SGAs) is mainly supported by very recent literature (Currel et al., 2017; Faay et al., 2018; Ostinelli et al., 2018a, b; Powney et al., 2012). In our sample, Haloperidol and Zuclopenthixol were more frequently prescribed in aggressive than in non-aggressive patients. In addition, the average dose of Haloperidol and Zuclopenthixol prescribed for violent patients was higher than non-violent ones. This might indirectly indicate a greater effectiveness of first-generation antipsychotics (FGAs), when used at higher doses, on aggressive behaviors, also in light of previous literature data (Powney et al., 2012). We can speculate that, in the psychiatric service examined in the present study, Haloperidol was likely considered to be the most effective compound for aggression as well as the most frequently used, despite its known side effects, including tardive dyskinesias (Carbon et al., 2018).

Fig. 2 Distribution of antipsychotics prescription in non-aggressive vs aggressive patients. Values are expressed as percentage
Regarding the treatment of aggressive behaviors in patients with personality disorders, it needs to be taken into account that antipsychotics are indicated only for aggressive behaviors associated with psychotic disorders, as activation of dopamine receptor may lead to defensive aggression (Tsiouris, 2009). Indeed, there is no evidence that antipsychotics are effective in controlling aggression in patients suffering from personality disorders. On the other hand, Quetiapine was shown to be effective in the treatment of aggression, impulsivity, and irritability and has proved to be an effective medication in patients with antisocial personality disorder. In addition, its better tolerability profile may determine a major therapeutic compliance (Walker et al., 2013). Consistently, in our sample, the third most used antipsychotic for aggressive patients was Quetiapine.

Among SGAs, strong evidence supports the use of Clozapine for treating psychotic aggression in refractory patients and for impulsive violence (Mauri et al., 2003; Meyer et al., 2016). In our sample, the frequency of Clozapine use was higher in violent than in nonviolent patients. In terms of effectiveness for aggression, in a previous study, Clozapine was followed by Olanzapine (Citrome & Volavka, 2014) which was the second most administered drug in our sample, after Haloperidol.

Finally, the evidence for non-pharmacological interventions in reducing aggression and violence in psychiatric disorders is not conclusive, since high-quality RCTs are lacking (Rampling et al., 2016). In our sample, patients who were not currently on psychotherapy were found to be more aggressive than patients who were receiving it. Actually, some cognitive impairment was shown to be involved in the genesis and maintenance of violent behaviors in individuals with schizophrenia (Darmedru et al., 2017). Therefore, its effective management should contemplate new therapeutic perspectives such as cognitive remediation (which is still rarely used for this purpose) to complement the action of pharmacotherapy (Darmedru et al., 2018).

Additional data concerning sociodemographic factors has been discussed elsewhere (Mauri et al., 2019).

The following methodological limitations should be considered when interpreting the abovementioned findings. First of all, the nature of the study was observational, although the raters were blinded to study aim and to the administered drugs. Moreover, the present investigation did not include any measure of efficacy. Thus, we cannot conclude that the efficacy of Haloperidol is greater than that of any other specific antipsychotic for the treatment of aggressiveness. In addition, we could not control bias or confounding factors, as a RCT would allow. On the other hand, it has been postulated that an observational design may be more suitable in evaluating a population of patients that is often difficult to engage with and unlikely to participate in RCTs. Furthermore, the study should continue involving other psychiatric services, including SERD and CPS located in other areas of the city as also economic, cultural, and other factors related to the catchment area may have played a role in the reported results.

**Conclusion**

Our results confirm the well-established relationship between substance abuse and violent behavior in outpatients with psychiatric disorders attending psychosocial community centers (Fig. 1). The pharmacological approach psychiatrists considered clinically more appropriate in treating aggressive behaviors was analyzed in terms of most widely used treatments in aggressive versus non-aggressive outpatients. In particular, the frequency...
and dosages of Haloperidol and Zuclopenthixol administration were higher in aggressive versus non-aggressive patients. Among SGAs, Clozapine was found to be preferred in the treatment of aggressive patients. These results do not necessarily mean that FGAs are more effective than SGAs in the treatment of aggressive outpatients. As Clozapine, despite being a SGA, is the oldest SGA, reported results seem to suggest that mental health professionals working in psychosocial community centers need to be educated and trained about most effective treatments—not necessarily antipsychotic monotherapies—for mitigating violent behaviors. In this regard, in fact, more recent literature data seem to suggest a wider use of newer SGAs, such as Risperidone, Paliperidone, and Quetiapine, also in light of a better tolerability profile (Currel et al., 2017; Faay et al., 2018; Ostinelli et al., 2018a, b; Victoroff et al., 2014; Walker et al., 2013).

Ultimately, the effectiveness of psychotropic drugs on aggressive behaviors still remains unclear with further studies needed in the area of outpatients. Reported real-world findings on this topic may help clinicians to reach a more conscious drug choice, while further studies in the field are warranted.

Acknowledgements The authors acknowledge the patients included in the study.

Author Contribution All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Massimo C. Mauri, Giovanna Cirnigliaro, and Bernardo Dell’Osso. The first draft of the manuscript was written by Giovanna Cirnigliaro and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.

Declarations

Ethics Approval All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).

Informed Consent Informed consent was obtained from all patients for being included in the study.

Conflict of Interest Prof. Dell’Osso has received speaker fees from Lundbeck, Angelini, Janssen, Livanova, Arcapharma, and Neuraxpharm. The other authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Amore, M., Menchetti, M., Tonti, C., Scarlatti, F., Lundgren, E., Esposito, W., & Berardi, D. (2008). Predictors of violent behavior among acute psychiatric patients: Clinical study. Psychiatry and Clinical Neurosciences, 62(3), 247–255. https://doi.org/10.1111/j.1440-1819.2008.01790.x
Amore, M., Tonti, C., Esposito, W., Baratta, S., Berardi, D., & Menchetti, M. (2013). Course and predictors of physical aggressive behaviour after discharge from a psychiatric inpatient unit: 1 year follow-up. *Community Mental Health Journal, 49*(4), 451–456. https://doi.org/10.1007/s10597-012-9530-1

Arango, C., & Bernardo, M. (2005). The effect of quetiapine on aggression and hostility in patients with schizophrenia. *Human Psychopharmacology, 20*, 237–241. https://doi.org/10.1002/hup.686

Arseneault, L., Moffitt, T. E., Caspi, A., Taylor, P. J., & Silva, P. A. (2000). Mental disorders and violence in a total birth cohort. *Arch Gen Psychiatry*, 57(10), 979–86. https://doi.org/10.1001/archpsyc.57.10.979.

Ballnerini, A., Boccalon, R., Boncompagni, G., Casacchia, M., Margari, F., Minervini, L., & Saltari, A. (2007). An observational study in psychiatric acute patients admitted to General Hospital Psychiatric Wards in Italy. *Annals of General Psychiatry, 6*, 2. https://doi.org/10.1186/1744-859X-6-2

Biancosino, B., Delmonte, S., Grassi, L., Santone, G., Preti, A., Miglio, R., & de Girolamo, G. (2009). Ballerini, A., Boccalon, R., Boncompagni, G., Casacchia, M., Margari, F., Minervini, L., & Saltari, A.

Buckley, P. F., Ibrahim, Z. Y., Singer, B., & Orr, B. (1997). Aggression and schizophrenia: Efficacy of risperidone. *Journal of the American Academy of Psychiatry and the Law, 25*(2), 173–181.

Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018). Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. *World Psychiatry*, 17(3), 330–340. https://doi.org/10.1002/wps.20579.

Choe, J. Y., Teplin, L. A., & Abram, K. M. (2008). Perpetration of violence, violent balancing public health concerns. *Psychiatric Services S2-Hospital & Community Psychiatry, 59*(2), 153–164. https://doi.org/10.1176/appi.ps.59.2.153

Citrome, L., & Volavka, J. (2014). The psychopharmacology of violence: Making sensible decisions. *CNS Spectrums, 19*(5), 411–418. https://doi.org/10.1016/j.jcns.2007.09.005

Colasanti, A., Natoli, A., Molitero, D., Rossattini, M., De Gaspari, I. F., & Mauri, M. C. (2008). Psychiatric diagnosis and aggression before acute hospitalisation. *European Psychiatry, 23*(6), 441–448. https://doi.org/10.1016/j.eurpsy.2007.09.005

Cornaggia, C. M., Beghi, M., Pavone, F., & Barale, F. (2011). Aggression in psychiatry wards: A systematic review. *Psychiatry Research, 189*(1), 10–20. https://doi.org/10.1016/j.pscychresns.2010.12.024

Currel, C. U., Yu, X., & Xiang, Y. (2017). Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. *Annals of Clinical Psychiatry, 29*(2), 92–102.

Dack, C., Ross, J., Papadopoulos, C., Stewart, D., & Bowers, L. (2013). A review and meta-analysis of the factors associated with psychiatric in-patient aggression. *Acta Psychiatrica Scandinavica*. https://doi.org/10.1111/acps.12053

Darmedru, C., Demily, C., & Franck, N. (2017). Cognitive remediation and social cognitive training for violence in schizophrenia: A systematic review. *Psychiatry Research*. Elsevier Ireland Ltd. https://doi.org/10.1016/1074-8481(98)00054-0

Darmedru, C., Demily, C., & Franck, N. (2018). Preventing violence in schizophrenia with cognitive remediation. *Encephale, 44*(2), 158–167. https://doi.org/10.1016/j.encep.2017.05.001

Elbogen, E. B., & Johnson, S. C. (2009). The Intricate link between violence and mental disorder results from the national epidemiologic survey on alcohol and related conditions. *Archives of General Psychiatry, 66*(2), 152–161. https://doi.org/10.1001/archgenpsychiatry.2008.537

Faay, M. D. M., Czobor, P., & Sommer, I. (2018). Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: A review and meta-analysis. *Neuropsychopharmacology, 43*, 2340–2349.

Fazel, S., Gulati, G., Linsell, L., Geddes, J. R., & Grann, M. (2009a). Schizophrenia and Violence: Systematic Review and Meta-Analysis. *PLoS Med 6*(8):e1000120. https://doi.org/10.1371/journal.pmed.1000120

Fazel, S., Langström, N., Hjern, A., Grann, M., & Lichtenstein, P. (2009b). Schizophrenia, substance abuse, and violent crime. *JAMA - Journal of the American Medical Association, 301*(19), 2016–2023. https://doi.org/10.1001/jama.2009.675
Fazel, S., Lichtenstein, P., Grann, M., Goodwin, G. M., & Långström, N. (2010). Bipolar disorder and violent crime: New evidence from population-based longitudinal studies and systematic review. *Archives of General Psychiatry, 67*(9), 931–938. https://doi.org/10.1001/archgenpsychiatry.2010.97

Fazel, S., Zetterqvist, J., Larsson, H., Långström, N., & Lichtenstein, P. (2014). Antipsychotics, mood stabilisers, and risk of violent crime. *The Lancet, 384*(9949), 1206–1214. https://doi.org/10.1016/S0140-6736(14)60379-2

Ferns, T., & Cork, A. (2008). Managing alcohol related aggression in the emergency department (Part I). *International Emergency Nursing, 16*(1), 43–47. https://doi.org/10.1016/j.ienej.2007.12.001

Foley, S. R., Kelly, B. D., Clarke, M., McTigue, O., Gervin, M., Kamali, M., & Browne, S. (2005). Incidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosis. *Schizophrenia Research, 72*(2–3), 161–168. https://doi.org/10.1016/j.schres.2004.03.010

Folgo, A. R., & Iennaco, J. D. S. (2020). Staff perceptions of risk factors for violence and aggression in ambulatory care. *Work, 65*(2), 435–445. https://doi.org/10.3233/WOR-203096

Gerra, G., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., Mossini, M., & Brambilla, F. (2004). Aggressive responding in abstinent heroin addicts: Neuroendocrine and personality correlates. *Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28*(1), 129–139. https://doi.org/10.1016/j.pnpbp.2003.09.029

Gillings, M., Grundlingh, J., & Aw-Yong, M. (2016). Guidelines for the Management of Excited Delirium / Acute Behavioural Disturbance (ABD). *The Royal College of Emergency Medicine Best Practice Guideline, 1–15*. https://rcem.ac.uk/wpcontent/uploads/2021/10/RCEM_Guidelines_for_Management_of_AcuteBehavioural_Disturbance_May2016.pdf

He, J., Hong, W., Shao, Y., Han, H., & Xie, B. (2017). Application of MOAS for evaluating of violence risk in the inpatients with mental disorders. *Fa Yi Xue Za Zhi, 33*(1), 28–31. https://doi.org/10.3969/j.issn.1004-5619.2017.01.007

Huband, N., Ferriter, M., Nathan, R., & Jones, H. (2014). Antiepileptics for aggression and associated impulsivity. *Cochrane Database of Systematic Reviews, Europe PMC, (October 2009).* https://doi.org/10.1002/14651858.CD003499.pub3

Kay, S. R., Wolkenfeld, F., & Murrill, L. M. (1988). Profiles of aggression among psychiatric patients. *I. Nature and prevalence. The Journal of Nervous and Mental Disease, 176*(9), 539–546. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3418327

Kirsch, P., Ronshausen, S., Mier, D., & Gallhofer, B. (2007). The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. *Pharmacopsychiatry, 40*(5), 196–198. https://doi.org/10.1055/s-2007-984463

Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Archives of General Psychiatry, 63*(6), 622. https://doi.org/10.1001/archpsyc.63.6.622

Li, W., Yang, Y., Hong, L., An, F. R., Ungvari, G. S., Ng, C. H., & Xiang, Y. T. (2020). Prevalence of aggression in patients with schizophrenia: A systematic review and meta-analysis of observational studies. *Asian Journal of Psychiatry*. Elsevier BV. https://doi.org/10.1016/j.ajp.2019.101846

Lindenmayer, J. P., & Kanellopoulou, I. (2009). Schizophrenia with impulsive and aggressive behaviors. *Psychiatric Clinics of NA, 32*(4), 885–902. https://doi.org/10.1016/j.psc.2009.08.006

Maremmani, A. G., Rugani, F., Bacciardi, S., Rovai, L., Pacini, M., Dell’Osso, L., & Maremmani, I. (2014). Does dual diagnosis affect violence and moderate/superficial self-harm in heroin addiction at treatment entry? *Journal of Addiction Medicine, 8*(2), 116–122. https://doi.org/10.1097/ADM.0000000000000019

Margari, F., Matarazzo, R., Cassacchia, M., Roncone, R., Dieci, M., Safran, S., & Simoni, L. (2005). Italian validation of MOAS and NOSIE: A useful package for psychiatric assessment and monitoring of aggressive behaviours. *International Journal of Methods in Psychiatric Research, 14*(2), 109–118. https://doi.org/10.1002/mpr.22

Mathers, C., Fat, D., & Boema, J. (2008). *The global burden of disease: 2004 Update*. World Health Organization.

Mauri, M. C., Volonteri, L. S., Dell’Osso, B., Regispani, F., Papa, P., Baldi, M., & Bareggi, S. R. (2003). Predictors of clinical outcome in schizophrenic patients responding to clozapine. *Journal of Clinical Psychopharmacology, 23*(6), 660–664. https://doi.org/10.1097/01.jcp.0000095351.32154.3a

Mauri, M. C., Rovera, C., Paletta, S., De Gaspari, I. F., Maffini, M., & Altamura, A. C. (2011). Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation. *Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35*(7), 1631–1635. https://doi.org/10.1016/j.pnpbp.2011.05.008
Mauri, M. C., Cirnigliaro, G., Di Pace, C., Paletta, S., Reggiori, A., Altamura, C., & Dell’Osso, B. (2019). Aggressiveness and violence in psychiatric patients: A clinical or social paradigm? CNS Spectrums, 1, 1–10. https://doi.org/10.1017/S1092852918001438

McNaughton Reyes, H. L., Foshee, V. A., Bauer, D. J., & Ennett, S. T. (2014). Proximal and time-varying effects of cigarette, alcohol, marijuana and other hard drug use on adolescent dating aggression. Journal of Adolescence, 37(3), 281–289. https://doi.org/10.1016/j.adolescence.2014.02.002

Meyer, J. M., Cummings, M. A., Proctor, G., & Stahl, S. M. (2016). Psychopharmacology of persistent violence and aggression. Psychiatric Clinics of North America, 39(4), 541–556. https://doi.org/10.1016/j.psc.2016.07.012

Mizrahi, R., Korostil, M., Starkstein, S., & Zipursky, R. (2007). The effect of antipsychotic treatment on Theory of Mind. Psychological Medicine, 37(4), 595–601. https://doi.org/10.1017/S0033291706009342

Morrisette, D. A., & Stahl, S. M. (2013). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums. Cambridge University Press. https://doi.org/10.1017/S1092852914000388

Ostinelli, E., Brooke-powney, M., Li, X., & Ce, A. (2017). Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) (Review). Cochrane Database of Systematic Reviews, CD009377(7). https://doi.org/10.1002/14651858.CD009377.pub3. www.cochranelibrary.com

Ostinelli, E., Hussein, M., & Hamed, U. (2018a). Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Database of Systematic Reviews, 4. CD009412. https://doi.org/10.1002/14651858.CD009412.pub2

Ostinelli, E., Jajawi, S., Spyridi, S., Sayal, K., & Mb, J. (2018b). Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation) (Review) Summary of findings for the main comparison. Cochrane Database Syst Rev, CD008074(1). https://doi.org/10.1002/14651858.CD008074.pub2. www.cochranelibrary.com

Patchan, K., Vyas, G., Hackman, A., Mackowick, M., Richardson, C., Love, R., & Kelly, D. (2018). Clozapine in reducing aggression and violence in forensic populations. Psychiatric Quarterly, 89(1), 157–168. https://doi.org/10.1007/s11126-017-9521-z

Penzner, J. B., Dudas, M., Saito, E., Olshanskiy, V., Parikh, U. H., Kapoor, S., & Correll, C. U. (2009). Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. Journal of Child and Adolescent Psychopharmacology, 19(5), 563–573. https://doi.org/10.1089/cap.2009.0051

Phillips, P. (2000). Substance misuse, offending and mental illness: a review. Journal of Psychiatric and Mental Health Nursing., 7(6), 483–489. https://doi.org/10.1046/j.1365-2850.2000.00334.x ACM01 696967

Pinna, F., Tusconi, M., Dessi, C., Pittaluga, G., Fiorillo, A., & Carpintiello, B. (2016). Violence and mental disorders. A retrospective study of people in charge of a community mental health center. International Journal of Law and Psychiatry, 47, 122–128. https://doi.org/10.1016/j.ijlp.2016.02.015

Powney, M. J., Adams, C. E., & Jones, H. J. (2012). Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Database of Systematic Reviews, 11(11), CD009377. https://doi.org/10.1002/14651858.CD009377.pub2

Rampling, J., Furtado, V., Winsper, C., Marwaha, S., Lucca, G., Livianou, M., & Singh, S. P. (2016). Non-pharmacological interventions for reducing aggression and violence in serious mental illness: A systematic review and narrative synthesis. European Psychiatry. Elsevier Masson SAS. https://doi.org/10.1016/j.eurpsy.2016.01.2422

Renwick, L., Stewart, D., Richardson, M., Lavelle, M., James, K., Hardy, C., & Bowers, L. (2016). Aggression on inpatient units: Clinical characteristics and consequences. International Journal of Mental Health Nursing, 25(4), 308–318. https://doi.org/10.1111/inm.12191

Reyes, H. L. M. N., Foshee, V. A., Tharp, A. T., Ennett, S. T., & Bauer, D. J. (2015). Substance use and physical dating violence: The role of contextual moderators. American Journal of Preventive Medicine, 49(3), 467–475. https://doi.org/10.1016/j.amepre.2015.05.018

Swanson, W., Swartz, S., Essock, M., & Osher, C. (2002). The social-environmental context of violent behavior in persons treated for severe mental illness. American Journal of Public Health, 92(9), 1523–1531.

Szabo, K., White, C., Cummings, S., & Wang, R. (2015). Inpatient aggression in community hospitals. CNS Spectrums, 20(3), 223–230. https://doi.org/10.1017/S1092852914000820
Tsiouris, J. (2009). Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: Treatment or mistreatment? *Journal of Intellectual Disability Research.* [https://doi.org/10.1111/j.1365-2788.2009.01232.x](https://doi.org/10.1111/j.1365-2788.2009.01232.x)

van Schalkwyk, G. I., Beyer, C., Johnson, J., Deal, M., & Bloch, M. H. (2018). Antipsychotics for aggression in adults: A meta-analysis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry,* 81(July 2017), 452–458. [https://doi.org/10.1016/j.pnpbp.2017.07.019](https://doi.org/10.1016/j.pnpbp.2017.07.019)

Victoroff, J., Coburn, K., Reeve, A., Sampson, S., & Shillcutt, S. (2014). Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: A systematic review. *Journal of Neuropsychiatry and Clinical Neurosciences,* 26(4), 283–312. [https://doi.org/10.1176/appi.neuropsych.13110335](https://doi.org/10.1176/appi.neuropsych.13110335)

Walker, C., Thomas, J., & Allen, T. (2013). Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. *International Journal of Offender Therapy and Comparative Criminology,* 47(5), 556–557. [https://doi.org/10.1177/0306624X03253027](https://doi.org/10.1177/0306624X03253027)

Witt, K., van Dorn, R., & Fazel, S. (2013). Risk factors for violence in psychosis: Systematic review and meta-regression analysis of 110 studies. *PLoS ONE,* 8(2). [https://doi.org/10.1371/journal.pone.0055942](https://doi.org/10.1371/journal.pone.0055942)

Wolf, A., Gray, R., & Fazel, S. (2014). Violence as a public health problem: An ecological study of 169 countries. *Social Science and Medicine,* 104, 220–227. [https://doi.org/10.1016/j.socscimed.2013.12.006](https://doi.org/10.1016/j.socscimed.2013.12.006)

World Health Organization. A. (Ed.). (1993). *The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research* (Vol. 2).

Yudofsky, S. C., Silver, J. M., Jackson, W., Endicott, J., & Williams, D. (1986). The Overt Aggression Scale for the objective rating of verbal and physical aggression. *The American Journal of Psychiatry,* 143(1), 35–39. [https://doi.org/10.1176/ajp.143.1.35](https://doi.org/10.1176/ajp.143.1.35)

Zaman, H., Sampson, S., & Beck, A. (2017). Benzodiazepines for psychosis-induced aggression or agitation (Review). *Cochrane Database of Systematic Reviews,* 12, CD003079.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Authors and Affiliations**

Massimo Carlo Mauri¹ · Giovanna Cirnigliaro² · Eleonora Piccoli² · Matteo Vismara² · Vera De Carlo² · Nicolaja Girone² · Bernardo Dell’Osso²,³,⁴,⁵

¹ Department of Neuroscience and Mental Health, Clinical Psychopharmacology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122 Milan, Italy

² Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, ASST Sacco-Fatebenefratelli, University of Milan, Via G.B. Grassi, 74, 20157 Milan, Italy

³ Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University, Stanford, CA, USA

⁴ Aldo Ravelli” Center for Neurotechnology and Brain Therapeutic, University of Milan, Milan, Italy

⁵ “Centro per lo studio dei meccanismi molecolari alla base delle patologie neuro-psico-geriatriche”, University of Milan, Milan, Italy